{"title":"抗血管内皮生长因子治疗与脉络膜骨瘤相关的脉络膜新生血管:一个基于案例研究的回顾。","authors":"Sahba Fekri, Amir Hossein Farahi, Maryam Zamani","doi":"10.4103/joco.joco_74_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To present a 13-year-old patient with choroidal osteoma complicated by choroidal neovascularization (CNV) treated with antivascular endothelial growth factor (anti-VEGF) agents and to review the efficacy of these agents based on relevant literature.</p><p><strong>Methods: </strong>Case report.</p><p><strong>Results: </strong>A 13-year-old girl presented with sudden visual loss in her right eye. Ophthalmic examination revealed a large choroidal osteoma complicated by subretinal and subretinal pigment epithelium (sub-RPE) hemorrhage, suggestive of CNV. Intravitreal bevacizumab injections were administered, leading to substantial improvement in vision and resolution of subretinal and sub-RPE hemorrhage. Follow-up showed that further injections were unnecessary as the CNV regressed. Literature review identified 25 cases of CNV associated with choroidal osteoma, with bevacizumab being the most frequently used anti-VEGF agent. Multiple injections were often required, though single-dose injections also proved effective in some cases. The majority of patients experienced visual improvement following treatment.</p><p><strong>Conclusion: </strong>Anti-VEGF agents, like bevacizumab, appear to be a promising treatment option for CNV secondary to choroidal osteoma, potentially preserving and improving vision with limited injections.</p>","PeriodicalId":15423,"journal":{"name":"Journal of Current Ophthalmology","volume":"36 4","pages":"462-467"},"PeriodicalIF":0.9000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487803/pdf/","citationCount":"0","resultStr":"{\"title\":\"Antivascular Endothelial Growth Factors for the Management of Choroidal Neovascularization Associated with Choroidal Osteoma: A Case Study-Based Review.\",\"authors\":\"Sahba Fekri, Amir Hossein Farahi, Maryam Zamani\",\"doi\":\"10.4103/joco.joco_74_24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To present a 13-year-old patient with choroidal osteoma complicated by choroidal neovascularization (CNV) treated with antivascular endothelial growth factor (anti-VEGF) agents and to review the efficacy of these agents based on relevant literature.</p><p><strong>Methods: </strong>Case report.</p><p><strong>Results: </strong>A 13-year-old girl presented with sudden visual loss in her right eye. Ophthalmic examination revealed a large choroidal osteoma complicated by subretinal and subretinal pigment epithelium (sub-RPE) hemorrhage, suggestive of CNV. Intravitreal bevacizumab injections were administered, leading to substantial improvement in vision and resolution of subretinal and sub-RPE hemorrhage. Follow-up showed that further injections were unnecessary as the CNV regressed. Literature review identified 25 cases of CNV associated with choroidal osteoma, with bevacizumab being the most frequently used anti-VEGF agent. Multiple injections were often required, though single-dose injections also proved effective in some cases. The majority of patients experienced visual improvement following treatment.</p><p><strong>Conclusion: </strong>Anti-VEGF agents, like bevacizumab, appear to be a promising treatment option for CNV secondary to choroidal osteoma, potentially preserving and improving vision with limited injections.</p>\",\"PeriodicalId\":15423,\"journal\":{\"name\":\"Journal of Current Ophthalmology\",\"volume\":\"36 4\",\"pages\":\"462-467\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2025-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487803/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Current Ophthalmology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/joco.joco_74_24\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Current Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/joco.joco_74_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Antivascular Endothelial Growth Factors for the Management of Choroidal Neovascularization Associated with Choroidal Osteoma: A Case Study-Based Review.
Purpose: To present a 13-year-old patient with choroidal osteoma complicated by choroidal neovascularization (CNV) treated with antivascular endothelial growth factor (anti-VEGF) agents and to review the efficacy of these agents based on relevant literature.
Methods: Case report.
Results: A 13-year-old girl presented with sudden visual loss in her right eye. Ophthalmic examination revealed a large choroidal osteoma complicated by subretinal and subretinal pigment epithelium (sub-RPE) hemorrhage, suggestive of CNV. Intravitreal bevacizumab injections were administered, leading to substantial improvement in vision and resolution of subretinal and sub-RPE hemorrhage. Follow-up showed that further injections were unnecessary as the CNV regressed. Literature review identified 25 cases of CNV associated with choroidal osteoma, with bevacizumab being the most frequently used anti-VEGF agent. Multiple injections were often required, though single-dose injections also proved effective in some cases. The majority of patients experienced visual improvement following treatment.
Conclusion: Anti-VEGF agents, like bevacizumab, appear to be a promising treatment option for CNV secondary to choroidal osteoma, potentially preserving and improving vision with limited injections.
期刊介绍:
Peer Review under the responsibility of Iranian Society of Ophthalmology Journal of Current Ophthalmology, the official publication of the Iranian Society of Ophthalmology, is a peer-reviewed, open-access, scientific journal that welcomes high quality original articles related to vision science and all fields of ophthalmology. Journal of Current Ophthalmology is the continuum of Iranian Journal of Ophthalmology published since 1969.